FDA
-
-
-
-
-
-
-
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
-
-
-
-
-
-
-
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
-
-
-
-
-
327,063 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

